Beractant

證據等級: L5

預測適應症: 0 個

Beractant: Pulmonary Surfactant — No New Indication Predicted

One-Sentence Summary

Beractant is a natural bovine pulmonary surfactant indicated for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. The TxGNN model did not generate any predicted new indications for this drug. Combined with significant data gaps in mechanism of action and safety information, this candidate currently lacks sufficient basis for drug repurposing evaluation.

Quick Overview

Item	Content
Original Indication	Neonatal Respiratory Distress Syndrome (RDS) — licence text not available in data
Predicted New Indication	None (no TxGNN prediction generated)
TxGNN Prediction Score	N/A
Evidence Level	L5 — No prediction, no supporting studies
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	2
Recommended Decision	Hold

Why Is There No Prediction?

Beractant (brand name: Survanta) is a bovine-derived lung surfactant extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins (SP-B and SP-C). It works by reducing surface tension at the air–liquid interface of the alveoli, preventing alveolar collapse in premature neonates whose lungs have not yet produced sufficient endogenous surfactant.

The TxGNN model did not produce any repurposing candidates for beractant. This may be due to several factors:

Highly specialised mechanism: Beractant acts as a physical surfactant replacement rather than through a conventional pharmacological target (receptor, enzyme, or pathway). Knowledge graph–based models like TxGNN rely on drug–target–disease linkages, and beractant’s mechanism does not map well to typical druggable targets.
Limited knowledge graph connectivity: As a biologically derived surfactant, beractant may have sparse connections in the TxGNN knowledge graph (few recorded drug–target or drug–gene interactions in DrugBank), reducing the model’s ability to infer novel disease associations.
Niche clinical use: Beractant is administered intratracheally to neonates — a highly specialised route and population — which further limits cross-indication inference.

Clinical Trial Evidence

No predicted indication was generated by TxGNN; therefore, no targeted clinical trial search was performed for a repurposing direction.

Currently no related clinical trials for a new indication to report.

Literature Evidence

No predicted indication was generated by TxGNN; therefore, no targeted literature search was performed for a repurposing direction.

Currently no related literature for a new indication to report.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(not available)	(not available)	(not available)	(not available)

Two registrations are recorded in the NPRA database, but detailed licence information (authorisation numbers, product names, dosage forms, and approved indication text) was not captured in the current data extraction. Please query the NPRA Quest3+ portal directly for full details.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model did not generate any repurposing candidates for beractant. This is likely attributable to the drug’s unique mechanism as a physical surfactant replacement (rather than a conventional pharmacological agent), which results in limited connectivity within the knowledge graph. Without a predicted indication, there is no actionable repurposing hypothesis to evaluate.

To revisit this candidate, the following would be needed:

Enrichment of beractant’s knowledge graph node with additional drug–target and drug–pathway annotations (e.g., surfactant protein interactions, lipid metabolism pathways)
Detailed mechanism of action data (currently a data gap)
Complete NPRA licence information (authorisation numbers, product names, approved indication text)
Package insert safety data (key warnings, contraindications)
Consider whether alternative surfactant preparations (poractant alfa, calfactant) have richer KG data that could inform cross-referencing

Disclaimer: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.